
Jan 12 (Reuters) - Nuvation Bio Inc NUVB.N:
NUVATION BIO AND EISAI ENTER INTO EXCLUSIVE LICENSING AGREEMENT FOR TALETRECTINIB IN EUROPE AND ADDITIONAL COUNTRIES OUTSIDE U.S., CHINA AND JAPAN
NUVATION BIO INC - TO RECEIVE UP TO €195 MILLION IN PAYMENTS
NUVATION BIO INC - EISAI RECEIVES EXCLUSIVE RIGHTS FOR TALETRECTINIB IN MULTIPLE REGIONS
NUVATION BIO INC: MAA FOR TREATMENT OF ADVANCED ROS1+ NSCLC IS EXPECTED TO BE FILED IN EUROPE IN FIRST HALF OF 2026
NUVATION BIO INC - MAA FOR TALETRECTINIB EXPECTED IN EUROPE IN 2026